TY - JOUR
T1 - Enoyl-coenzyme A hydratase and antigen 85B of Mycobacterium habana are specifically recognized by antibodies in sera from leprosy patients
AU - Serafín-López, J.
AU - Talavera-Paulin, M.
AU - Amador-Molina, J. C.
AU - Alvarado-Riverón, M.
AU - Vilchis-Landeros, M. M.
AU - Méndez-Ortega, P.
AU - Fafutis-Morris, M.
AU - Paredes-Cervantes, V.
AU - López-Santiago, R.
AU - León, C. I.
AU - Guerrero, M. I.
AU - Ribas-Aparicio, R. M.
AU - Mendoza-Hernández, G.
AU - Carreño-Martínez, C.
AU - Estrada-Parra, S.
AU - Estrada-García, I.
PY - 2011/7
Y1 - 2011/7
N2 - Leprosy is an infectious disease caused by Mycobacterium leprae, which is a noncultivable bacterium. One of the principal goals of leprosy research is to develop serological tests that will allow identification and early treatment of leprosy patients. M. habana is a cultivable nonpathogenic mycobacterium and candidate vaccine for leprosy, and several antigens that cross-react between M. leprae and M. habana have been discovered. The aim of the present study was to extend the identification of cross-reactive antigens by identifying M. habana proteins that reacted by immunoblotting with antibodies in serum samples from leprosy patients but not with antibodies in sera from tuberculosis (TB) patients or healthy donors (HDs). A 28-kDa antigen that specifically reacted with sera from leprosy patients was identified. To further characterize this antigen, protein spots were aligned in two-dimensional polyacrylamide gels and Western blots. Spots cut out from the gels were then analyzed by mass spectrometry. Two proteins were identified: enoyl-coenzyme A hydratase (lipid metabolism; ML2498) and antigen 85B (Ag85B; mycolyltransferase; ML2028). These proteins represent promising candidates for the design of a reliable tool for the serodiagnosis of lepromatous leprosy, which is the most frequent form in Mexico.
AB - Leprosy is an infectious disease caused by Mycobacterium leprae, which is a noncultivable bacterium. One of the principal goals of leprosy research is to develop serological tests that will allow identification and early treatment of leprosy patients. M. habana is a cultivable nonpathogenic mycobacterium and candidate vaccine for leprosy, and several antigens that cross-react between M. leprae and M. habana have been discovered. The aim of the present study was to extend the identification of cross-reactive antigens by identifying M. habana proteins that reacted by immunoblotting with antibodies in serum samples from leprosy patients but not with antibodies in sera from tuberculosis (TB) patients or healthy donors (HDs). A 28-kDa antigen that specifically reacted with sera from leprosy patients was identified. To further characterize this antigen, protein spots were aligned in two-dimensional polyacrylamide gels and Western blots. Spots cut out from the gels were then analyzed by mass spectrometry. Two proteins were identified: enoyl-coenzyme A hydratase (lipid metabolism; ML2498) and antigen 85B (Ag85B; mycolyltransferase; ML2028). These proteins represent promising candidates for the design of a reliable tool for the serodiagnosis of lepromatous leprosy, which is the most frequent form in Mexico.
UR - http://www.scopus.com/inward/record.url?scp=79960148082&partnerID=8YFLogxK
U2 - 10.1128/CVI.00519-10
DO - 10.1128/CVI.00519-10
M3 - Artículo
C2 - 21613461
SN - 1556-6811
VL - 18
SP - 1097
EP - 1103
JO - Clinical and Vaccine Immunology
JF - Clinical and Vaccine Immunology
IS - 7
ER -